Epigenetic analysis of selective control of IL-17 production, and search for new strategy to treat chronic inflammation in collagen-diseases.
| Project/Area Number |
26670476
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Collagenous pathology/Allergology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
Usui Takashi 京都大学, 医学(系)研究科(研究院), その他 (90362483)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | GM-CSF / IL-17 / エピゲノム制御 / ヘルパーT細胞 / 間質性肺炎 / サイトカイン |
|---|
| Outline of Final Research Achievements |
IL-17 and the GM-CSF are important cytokines to maintain chronic inflammation of collagen diseases. In this project, we analyzed the mechanisms of production in-vitro and the treatment/intervention effects in-vivo of these cytokines.First, we established murine T cell clones which produce large amount of IL-17, and non-producer clones also. We found that gene-X controlled it through the methylation of the GC island of the IL-17 promoter domain. Second, we analyzed function of IL-17- and GM-CSF-producing cells using chronic/progressive interstitial pneumonitis model (SKG+zaymosan). We found the contribution of IL-17 was relatively low and GM-CSF was essential of this model. These findings suggest the new strategies to treat human collagen diseases which are un-met.
|
Report
(3 results)
Research Products
(6 results)
